| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | palmostatin B | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |